ASPHF (Ascentage Pharma Group International) Piotroski F-Score: 3 (As of Jun. 25, 2026) — 25% Below Median


ASPHF Ascentage Pharma Group International ASPHF
71 GF Score
Price $4.53
GF Value $6.61
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Piotroski F-Score?

Ascentage Pharma Group International ASPHF -3.51% 71 Piotroski F-Score is 3 as of Jun. 25, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates ASPHF with a GF Scoreâ„¢ of 71/100 and a GF Valueâ„¢ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,342 Biotechnology companies, Ascentage Pharma Group International ranks better than 55.14% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ascentage Pharma Group International has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Ascentage Pharma Group International's Piotroski F-Score or its related term are showing as below:

ASPHF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 3

During the past 10 years, the highest Piotroski F-Score of Ascentage Pharma Group International was 5. The lowest was 2. And the median was 4.

Ascentage Pharma Group International  (OTCPK:ASPHF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ascentage Pharma Group International Piotroski F-Score Related Terms


Ascentage Pharma Group International Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International Piotroski F-Score Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 2.00 5.00 3.00

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 0.00 5.00 0.00 3.00

ASPHF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Piotroski F-Score falls into.


ASPHF
71GF Score
Ascentage Pharma Group International ASPHF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was $-176.45 Mil.
Cash Flow from Operations was $-166.70 Mil.
Revenue was $81.51 Mil.
Gross Profit was $74.57 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (359.555 + 562.752) / 2 = $461.1535 Mil.
Total Assets at the begining of this year (Dec24) was $359.56 Mil.
Long-Term Debt & Capital Lease Obligation was $107.51 Mil.
Total Current Assets was $418.02 Mil.
Total Current Liabilities was $233.33 Mil.
Net Income was $-55.69 Mil.

Revenue was $134.69 Mil.
Gross Profit was $130.70 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (350.185 + 359.555) / 2 = $354.87 Mil.
Total Assets at the begining of last year (Dec23) was $350.19 Mil.
Long-Term Debt & Capital Lease Obligation was $122.16 Mil.
Total Current Assets was $202.48 Mil.
Total Current Liabilities was $160.23 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ascentage Pharma Group International's current Net Income (TTM) was -176.45. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ascentage Pharma Group International's current Cash Flow from Operations (TTM) was -166.70. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-176.449/359.555
=-0.49074272

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-55.686/350.185
=-0.1590188

Ascentage Pharma Group International's return on assets of this year was -0.49074272. Ascentage Pharma Group International's return on assets of last year was -0.1590188. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ascentage Pharma Group International's current Net Income (TTM) was -176.45. Ascentage Pharma Group International's current Cash Flow from Operations (TTM) was -166.70. ==> -166.70 > -176.45 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=107.513/461.1535
=0.23313929

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=122.163/354.87
=0.34424719

Ascentage Pharma Group International's gearing of this year was 0.23313929. Ascentage Pharma Group International's gearing of last year was 0.34424719. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=418.016/233.327
=1.79154577

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=202.475/160.233
=1.26362859

Ascentage Pharma Group International's current ratio of this year was 1.79154577. Ascentage Pharma Group International's current ratio of last year was 1.26362859. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ascentage Pharma Group International's number of shares in issue this year was 356.13. Ascentage Pharma Group International's number of shares in issue last year was 302.062. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=74.566/81.514
=0.91476311

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=130.697/134.692
=0.97033974

Ascentage Pharma Group International's gross margin of this year was 0.91476311. Ascentage Pharma Group International's gross margin of last year was 0.97033974. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=81.514/359.555
=0.22670801

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=134.692/350.185
=0.38463098

Ascentage Pharma Group International's asset turnover of this year was 0.22670801. Ascentage Pharma Group International's asset turnover of last year was 0.38463098. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ascentage Pharma Group International has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Ascentage Pharma Group International (ASPHF) has a Piotroski F-Score of 3 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ascentage Pharma Group International and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Ascentage Pharma Group International's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Ascentage Pharma Group International ranks #602 out of 1342 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Ascentage Pharma Group International's Piotroski F-Score too high?
Ascentage Pharma Group International's current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Ascentage Pharma Group International's value of 3 is 0% at this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #602 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascentage Pharma Group International has a GF Scoreâ„¢ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #602 out of 1342 companies for Piotroski F-Score. This puts Ascentage Pharma Group International in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Ascentage Pharma Group International's value of 3 is 0% at this benchmark. Historically, Ascentage Pharma Group International's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Ascentage Pharma Group International has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 0% at the Biotechnology industry median of 3.00. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Piotroski F-Score is 3 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
  • GF Score™: 71/100 with 7 warning signs
  • Industry Position: 0% at the Biotechnology median (#602 of 1342)

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score

Get the complete analysis for ASPHF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$6.61
GF Value